| Literature DB >> 33459533 |
Akira Okada1, Sachiko Ono2, Satoko Yamaguchi1, Hayato Yamana3, Kayo Ikeda Kurakawa1, Nobuaki Michihata3, Hiroki Matsui4, Masaomi Nangaku5, Toshimasa Yamauchi6, Hideo Yasunaga4, Takashi Kadowaki1,7.
Abstract
AIMS/Entities:
Keywords: Adherence; Clinical epidemiology; Nutrition guidance
Mesh:
Year: 2021 PMID: 33459533 PMCID: PMC8409872 DOI: 10.1111/jdi.13510
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Figure 1Study design and time course for the included patients. *We placed censoring weights for all included patients, considering those censored during the follow‐up period. **Each box represents 1 month. Max int, maximal interval; mo, months.
Characteristics of eligible patients with and without discontinuation of follow‐up visits for diabetes
| Variable | Category | No discontinuation | Discontinuation | |
|---|---|---|---|---|
| 5,194 | 1,314 | |||
| Age (years) | 20–39 | 261 (5.0%) | 87 (6.6%) | 0.006 |
| 40–49 | 1,848 (35.6%) | 412 (31.4%) | ||
| 50–59 | 2,103 (40.5%) | 569 (43.3%) | ||
| ≥60 | 982 (18.9%) | 246 (18.7%) | ||
| Sex | Male | 4,046 (77.9%) | 1,117 (85.0%) | <0.001 |
| Body mass index (kg/m2) | ≤18.49 | 69 (1.3%) | 10 (0.8%) | 0.410 |
| 18.50–24.99 | 1,830 (35.2%) | 470 (35.8%) | ||
| 25.00–29.99 | 2,129 (41.0%) | 538 (40.9%) | ||
| ≥30.00 | 1,165 (22.4%) | 292 (22.2%) | ||
| Missing | 1 (<0.1%) | 4 (0.3%) | ||
| Waist circumference (cm) | M: <85 cm, F: <90 cm | 1,544 (29.7%) | 366 (27.9%) | 0.200 |
| M: ≥85 cm, F: ≥90 cm | 3,497 (67.3%) | 905 (68.9%) | ||
| Missing | 153 (2.9%) | 43 (3.3%) | ||
| Fasting blood glucose (mg/dL) | 126–199 | 3,771 (72.6%) | 1,118 (85.1%) | <0.001 |
| ≥200 | 1,423 (27.4%) | 196 (14.9%) | ||
| HbA1c, % (mmol/mol) | 6.5–6.9 (48–52) | 1,214 (23.4%) | 557 (42.4%) | <0.001 |
| 7.0–7.9 (53–63) | 1,557 (30.0%) | 419 (31.9%) | ||
| 8.0–8.9 (64–74) | 710 (13.7%) | 119 (9.1%) | ||
| ≥9.0 (≥75) | 1,713 (33.0%) | 219 (16.7%) | ||
| Blood pressure | Normal | 3,349 (64.5%) | 867 (66.0%) | 0.080 |
| Grade 1 hypertension | 1,228 (23.6%) | 319 (24.3%) | ||
| Grade 2 hypertension | 451 (8.7%) | 97 (7.4%) | ||
| Grade 3 hypertension | 162 (3.1%) | 27 (2.1%) | ||
| Missing | 4 (0.1%) | 4 (0.3%) | ||
| Triglycerides (mg/dL) | <150 | 2,587 (49.8%) | 688 (52.4%) | 0.110 |
| 150–299 | 1,855 (35.7%) | 458 (34.9%) | ||
| ≥300 | 736 (14.2%) | 161 (12.3%) | ||
| Missing | 16 (0.3%) | 7 (0.5%) | ||
| LDL cholesterol (mg/dL) | <120 | 1,428 (27.5%) | 374 (28.5%) | 0.470 |
| 120–139 | 1,158 (22.3%) | 306 (23.3%) | ||
| ≥140 | 2,531 (48.7%) | 617 (47.0%) | ||
| Missing | 77 (1.5%) | 17 (1.3%) | ||
| HDL cholesterol (mg/dL) | <40 | 819 (15.8%) | 194 (14.8%) | 0.370 |
| ≥40 | 4,371 (84.2%) | 1,119 (85.2%) | ||
| Missing | 4 (0.1%) | 1 (0.1%) | ||
| Urinary protein dipstick test | − or ± | 4,388 (84.5%) | 1,151 (87.6%) | <0.001 |
| ≥+ | 713 (13.7%) | 132 (10.0%) | ||
| Missing | 93 (1.8%) | 31 (2.4%) | ||
| Antidyslipidemia prescription | + | 486 (9.4%) | 81 (6.2%) | <0.001 |
| Antihypertensive prescription | + | 975 (18.8%) | 159 (12.1%) | <0.001 |
| Insured person | Identical person | 4,034 (77.7%) | 1,116 (84.9%) | <0.001 |
| Dependent | 1,160 (22.3%) | 198 (15.1%) | ||
| Frequency of physician visits in previous year (months/year) | 0 | 1,074 (20.7%) | 304 (23.1%) | <0.001 |
| 1–4 | 1,825 (35.1%) | 522 (39.7%) | ||
| 5–12 | 2,295 (44.2%) | 488 (37.1%) | ||
| Frequency of alcohol intake | Rarely | 1,807 (34.8%) | 402 (30.6%) | <0.001 |
| Occasionally | 1,504 (29.0%) | 379 (28.8%) | ||
| Regularly | 1,096 (21.1%) | 344 (26.2%) | ||
| Missing | 787 (15.2%) | 189 (14.4%) | ||
| Smoking | – | 3,230 (62.2%) | 757 (57.6%) | 0.003 |
| + | 1,615 (31.1%) | 461 (35.1%) | ||
| Missing | 349 (6.7%) | 96 (7.3%) | ||
| Stage in change model for lifestyle modifications | Precontemplation | 620 (11.9%) | 183 (13.9%) | 0.050 |
| Contemplation | 1,488 (28.6%) | 378 (28.8%) | ||
| Determination | 865 (16.7%) | 244 (18.6%) | ||
| Action | 459 (8.8%) | 99 (7.5%) | ||
| Maintenance | 754 (14.5%) | 169 (12.9%) | ||
| Missing | 1,008 (19.4%) | 241 (18.3%) | ||
| Willingness to receive health instruction from public health nurses | – | 2,386 (45.9%) | 648 (49.3%) | 0.480 |
| + | 1,374 (26.5%) | 354 (26.9%) | ||
| Missing | 1,434 (27.6%) | 312 (23.7%) | ||
| Urinary protein/albumin quantitative test performed in first month | + | 802 (15.4%) | 115 (8.8%) | <0.001 |
| Ophthalmological examination performed in first month | + | 944 (18.2%) | 143 (10.9%) | <0.001 |
| Nutritional guidance performed in first month | + | 1,083 (20.9%) | 180 (13.7%) | <0.001 |
| Total cost in first month ($US) | ≤149 | 1,327 (25.5%) | 549 (41.8%) | <0.001 |
| 150–299 | 1,930 (37.2%) | 415 (31.6%) | ||
| ≥300 | 1,937 (37.3%) | 350 (26.6%) | ||
| Main visited medical facility (clinic or hospital) | Clinic | 3,382 (65.1%) | 866 (65.9%) | 0.590 |
| Hospital | 1,812 (34.9%) | 448 (34.1%) | ||
| Antidiabetic prescription in first month | + | 2,657 (51.2%) | 308 (23.4%) | <0.001 |
| HbA1c in previous year, % (mmol/L) | ≤6.4 (≤47) | 765 (14.7%) | 264 (20.1%) | 0.001 |
| ≥6.5 (≥48) | 1,136 (21.9%) | 288 (21.9%) | ||
| Missing | 3,293 (63.4%) | 762 (58.0%) | ||
| Fasting blood glucose in previous year (mg/dL) | ≤125 | 1,072 (20.6%) | 340 (25.9%) | 0.002 |
| ≥126 | 840 (16.2%) | 195 (14.8%) | ||
| Missing | 3,282 (63.2%) | 779 (59.3%) |
F, female; HbA1c, glycated hemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; M, male.
Figure 2Flow chart of patient selection. JMDC, Japanese administrative claims database.
Figure 3Kernel density plots showing the distributions of propensity scores in patients who received guideline‐recommended practices and those who did not (a) before and (b) after inverse probability of treatment weighting. (c) The standardized differences were smaller after inverse probability of treatment weighting. (a,b) Guideline practices, those who received guideline‐recommended practices; non‐guideline practices, those who did not receive guideline‐recommended practices. BMI, body mass index; BP, blood pressure; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; IPTW, inverse probability of treatment weighting; mo, months.
Characteristics of eligible patients before and after inverse probability of treatment weighting
| Variable | Category | Before IPTW | After IPTW | ||||
|---|---|---|---|---|---|---|---|
| Not receiving practices | Receiving practices | Standardized difference | Not receiving practices | Receiving practices | Standardized difference | ||
| Age (years) | 20–39 | 5.1 | 6.0 | 4.4 | 5.4 | 5.5 | 0.2 |
| 40–49 | 34.1 | 36.3 | 4.7 | 34.5 | 35.5 | 2.0 | |
| 50–59 | 42.3 | 38.2 | −8.4 | 40.8 | 39.6 | −2.4 | |
| ≥60 | 18.6 | 19.5 | 2.3 | 19.2 | 19.4 | 0.5 | |
| Sex | Male | 80.6 | 76.4 | −10.1 | 79.4 | 80.5 | 2.6 |
| Body mass index (kg/m2) | ≤18.49 | 1.1 | 1.6 | 4.2 | 1.1 | 1.1 | −0.1 |
| 18.50–24.99 | 34.1 | 38.4 | 9.1 | 35.2 | 35.1 | −0.3 | |
| 25.00–29.99 | 42.3 | 37.9 | −9.1 | 41.4 | 41.9 | 1.1 | |
| ≥30.00 | 22.5 | 22.1 | −0.9 | 22.3 | 21.9 | −0.9 | |
| Waist circumference (cm) | M: <85, F: <90 | 28.7 | 33.9 | 11.1 | 30.2 | 29.6 | −1.2 |
| M: ≥85, F: ≥90 | 71.3 | 66.1 | −11.1 | 69.8 | 70.4 | 1.2 | |
| Fasting blood glucose (mg/dL) | 126–199 | 79.4 | 65.1 | −32.3 | 75.9 | 76.0 | 0.3 |
| ≥200 | 20.6 | 34.9 | 32.3 | 24.1 | 24.0 | −0.3 | |
| HbA1c, % (mmol/mol) | 6.5–6.9 (48–52) | 29.8 | 21.1 | −20.1 | 27.5 | 28.0 | 1.2 |
| 7.0–7.9 (53–63) | 32.7 | 24.8 | −17.5 | 30.8 | 30.5 | −0.7 | |
| 8.0–8.9 (64–74) | 12.8 | 12.6 | −0.7 | 12.8 | 12.8 | 0.0 | |
| ≥9.0 (≥75) | 24.7 | 41.5 | 36.4 | 29.0 | 28.8 | −0.5 | |
| Blood pressure | Normal | 64.1 | 66.6 | 5.3 | 64.8 | 65.2 | 0.8 |
| Grade 1 hypertension | 24.5 | 22.2 | −5.6 | 24.1 | 24.0 | −0.2 | |
| Grade 2 hypertension | 8.5 | 8.3 | −0.5 | 8.3 | 8.3 | −0.1 | |
| Grade 3 hypertension | 2.9 | 2.9 | −0.1 | 2.8 | 2.6 | −1.4 | |
| Triglycerides (mg/dL) | <150 | 49.8 | 51.7 | 3.8 | 50.2 | 49.6 | −1.3 |
| 150–299 | 36.0 | 34.8 | −2.4 | 35.7 | 36.4 | 1.4 | |
| ≥300 | 14.2 | 13.4 | −2.2 | 14.1 | 14.0 | −0.2 | |
| LDL cholesterol (mg/dL) | <120 | 28.5 | 27.0 | −3.4 | 28.0 | 28.6 | 1.2 |
| 120–139 | 22.5 | 23.4 | 2.0 | 22.8 | 22.5 | −0.8 | |
| ≥140 | 48.9 | 49.6 | 1.3 | 49.1 | 48.9 | −0.4 | |
| HDL cholesterol (mg/dL) | <40 | 15.1 | 16.7 | 4.3 | 15.6 | 15.1 | −1.3 |
| ≥40 | 84.9 | 83.3 | −4.3 | 84.4 | 84.9 | 1.3 | |
| Urinary protein dipstick test | − or ± | 87.6 | 84.9 | −7.7 | 87.0 | 87.5 | 1.4 |
| ≥+ | 12.4 | 15.1 | 7.7 | 13.0 | 12.5 | −1.4 | |
| Anti‐dyslipidemia prescription | + | 9.9 | 5.9 | −14.6 | 8.7 | 8.3 | −1.4 |
| Anti‐hypertensive prescription | + | 19.8 | 11.8 | −22.1 | 17.3 | 16.1 | −3.1 |
| Insured person | Identical person | 80.1 | 76.8 | −8.1 | 79.4 | 80.2 | 1.9 |
| Dependent | 19.9 | 23.2 | 8.1 | 20.6 | 19.8 | −1.9 | |
| Frequency of physician visits in previous year (months/year) | 0 | 20.6 | 22.5 | 4.6 | 21.3 | 20.5 | −1.9 |
| 1–4 | 35.2 | 38.1 | 6.0 | 36.0 | 36.5 | 1.1 | |
| 5–12 | 44.2 | 39.4 | −9.7 | 42.7 | 43.0 | 0.6 | |
| Frequency of alcohol intake | Rarely | 38.8 | 41.8 | 6.0 | 39.6 | 40.0 | 0.7 |
| Occasionally | 34.0 | 34.5 | 1.2 | 34.2 | 33.6 | −1.3 | |
| Regularly | 27.2 | 23.7 | −8.1 | 26.2 | 26.4 | 0.6 | |
| Smoking | + | 34.9 | 33.1 | −3.9 | 34.4 | 35.0 | 1.3 |
| Stage in change model for lifestyle modifications | Precontemplation | 15.7 | 14.5 | −3.3 | 15.3 | 15.3 | 0.0 |
| Contemplation | 35.0 | 36.6 | 3.3 | 35.5 | 36.0 | 1.0 | |
| Preparation | 21.2 | 20.8 | −1.0 | 21.0 | 20.7 | −0.7 | |
| Action | 10.4 | 11.0 | 1.9 | 10.6 | 10.1 | −1.5 | |
| Maintenance | 17.7 | 17.1 | −1.5 | 17.6 | 17.9 | 0.7 | |
| Willingness to receive health instruction from public health nurses | + | 35.3 | 38.5 | 6.7 | 36.1 | 35.9 | −0.5 |
| Urinary protein/albumin quantitative test performed in first month | + | 8.5 | 27.4 | 50.8 | 13.4 | 14.2 | 2.3 |
| Total cost in first month (US$) | ≤149 | 35.0 | 14.1 | −50.1 | 29.0 | 27.6 | −2.9 |
| 150–299 | 38.3 | 30.7 | −16.0 | 36.4 | 35.9 | −1.1 | |
| ≥300 | 26.7 | 55.2 | 60.6 | 34.6 | 36.5 | 3.9 | |
| Main visited medical facility (clinic or hospital) | Clinic | 73.2 | 46.5 | −56.5 | 65.4 | 63.0 | −4.9 |
| Hospital | 26.8 | 53.5 | 56.5 | 34.6 | 37.0 | 4.9 | |
| Anti‐diabetic prescription in first month | + | 45.8 | 44.9 | −1.8 | 45.4 | 44.3 | −2.3 |
| HbA1c in previous year, % (mmol/mol) | ≤6.4 (≤47) | 40.9 | 35.3 | −11.6 | 39.4 | 38.4 | 1.91.9 |
| ≥6.5 (≥48) | 59.1 | 64.7 | 11.6 | 60.6 | 61.6 | 1.9 | |
| Fasting blood glucose in previous year (mg/dL) | ≤125 | 56.2 | 54.3 | −4.0 | 55.7 | 55.3 | −0.9 |
| ≥126 | 43.8 | 45.7 | 4.0 | 44.3 | 44.7 | 0.9 | |
Data are shown as percentages. F, female; HbA1c, glycated hemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; IPTW, inverse probability of treatment weighting; M, male.
Regression analysis of relative risks for interventions and discontinuation before and after inverse probability of treatment weighting
| Intervention | Model | Without intervention | With intervention | Relative risk | 95% CI | |
|---|---|---|---|---|---|---|
| Practices including nutritional guidance and ophthalmological examination | Before IPTW | 22.5% | 14.7% | 0.65 | 0.58–0.74 | <0.001 |
| After IPTW | 21.8% | 17.2% | 0.79 | 0.69–0.91 | 0.001 | |
| Nutritional guidance | Before IPTW | 21.6% | 14.3% | 0.66 | 0.57–0.76 | <0.001 |
| After IPTW | 21.1% | 15.9% | 0.75 | 0.62–0.90 | 0.002 | |
| Ophthalmological examination | Before IPTW | 21.6% | 13.2% | 0.61 | 0.52–0.72 | <0.001 |
| After IPTW | 20.7% | 19.3% | 0.93 | 0.74–1.17 | 0.551 |
CI, confidence interval; IPTW, inverse probability of treatment weighting.